Description
Book SynopsisLegalization of cannabis extracts around the world has led to a resurgence of interest into research surrounding endocannabinoids (eCBs) and the endocannabinoid system. This system is formed of a complex array of receptors, metabolic enzymes and transporters that finely tune the manifold biological activities of eCBs and there is an urgent need for the development of selective drugs to dissect the contribution of eCBs to the aetiology of various diseases. New Tools to Interrogate Endocannabinoid Signalling comprehensively covers the innovative research into both natural and synthetic compounds that affect this pathway and taking a target-based approach, assesses their potential for therapeutic use. With contributions from global leaders in the field, this timely volume will be a valuable resource to pharmaceutical researchers and medicinal chemists working in natural products and endocannabinoid drug discovery in academia and industry.
Table of ContentsQuest for Magic Bullets to Solve the Endocannabinoid Puzzle; Phytocannabinoids versus Endocannabinoids. A Modern View of the Endocannabinoid System; Natural Compounds and Synthetic Drugs to Target Type-1 Cannabinoid (CB1) Receptor; Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor; Natural and Synthetic Cannabinoids Targeting non-CB1, non-CB2 G Protein Coupled Receptors; Natural Compounds and Synthetic Drugs Targeting the Ionotropic Cannabinoid Members of Transient Receptor Potential (TRP) Channels; Inhibition of NAPE-PLD Activity by Natural Compounds and Synthetic Drugs, and its Biological Relevance; Natural Compounds and Synthetic Drugs to Target FAAH Enzyme; Natural and Synthetic Agents that Target Intracellular Monoacylglycerol Lipase (MGL) Activity; Small Molecule Inhibitors of Endocannabinoid Transport and Trafficking
